Relation

United Kingdom - London

• 15/03/2024
• Seed
• $35,000,000

We are an end-to-end biotech developing transformational medicines, with technology at our core.

Our ambition is to understand human biology in an unprecedented way; discovering therapies that will treat some of life's most devastating diseases. We leverage single-cell and multi-omics measurements directly from patient tissue, functional assays and machine learning to drive disease understanding — from cause to cure.

Medicines born from high-resolution biology, machine learning and clinical insights.

Our Lab-in-the-Loop seamlessly integrates single-cell analysis, genomics and machine learning. We have developed powerful technologies which we apply to select druggable targets and develop transformational medicines.

Related People

David RoblinFounder

United Kingdom - London, England

David Roblin is a distinguished scientist, physician, drug developer, and life-sciences executive. He has been involved in Relation since its founding, while engaged as CEO of Juvenescence Therapeutics, an early investor in Relation. Before joining Relation, he enjoyed a career in biotech, pharma and academia developing many important medicines in research, development, and commercial roles. Major roles include COO and Chair of Scientific Translation at the Francis Crick Institute and Head of European R&D for Pfizer. He is currently also a Non-Executive Director of Sosei (SOLTF), Non-Executive Chair of Centauri Therapeutics and remains Chair of Scientific Translation at the Crick.

LinkedIn https://www.linkedin.com/in/davidroblin/